Argenica Therapeutics Limited (ASX:AGN)

Market Cap	34.68M
Revenue (ttm)	3.21M +23.7%
Net Income	-7.17M
EPS	-0.06
Shares Out	128.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,612
Average Volume	273,706
Open	0.2750
Previous Close	0.2700
Day's Range	0.2700 - 0.2950
52-Week Range	0.1900 - 0.8850
Beta	0.75
RSI	51.09
Earnings Date	Feb 10, 2026

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AGN

Financial Performance

In fiscal year 2025, Argenica Therapeutics's revenue was 3.21 million, an increase of 23.70% compared to the previous year's 2.60 million. Losses were -7.17 million, 30.9% more than in 2024.